High Throughput Confined Migration Microfluidic Device for Drug Screening.

Cancer metastasis is the major cause of cancer-related death. Excessive extracellular matrix deposition and increased stiffness are typical features of solid tumors, creating confined spaces for tumor cell migration and metastasis. Confined migration is involved in all metastasis steps. However, confined and unconfined migration inhibitors are different and drugs available to inhibit confined migration are rare. The main challenges are the modeling of confined migration, the suffering of low throughput, and others. Microfluidic device has the advantage to reduce reagent consumption and enhance throughput. Here, a microfluidic chip that can achieve multi-function drug screening against the collective migration of cancer cells under confined environment is designed. This device is applied to screen out effective drugs on confined migration among a novel mechanoreceptors compound library (166 compounds) in hepatocellular carcinoma, non-small lung cancer, breast cancer, and pancreatic ductal adenocarcinoma cells. Three compounds that can significantly inhibit confined migration in pan-cancer: mitochonic acid 5 (MA-5), SB-705498, and diphenyleneiodonium chloride are found. Finally, it is elucidated that these drugs targeted mitochondria, actin polymerization, and cell viability, respectively. In sum, a high-throughput microfluidic platform for screening drugs targeting confined migration is established and three novel inhibitors of confined migration in multiple cancer types are identified.

[1]  G. Luker,et al.  High-Throughput Cellular Heterogeneity Analysis in Cell Migration at the Single-Cell Level. , 2022, Small.

[2]  R. Osellame,et al.  Microfluidic Lab-on-a-Chip for Studies of Cell Migration under Spatial Confinement , 2022, Biosensors.

[3]  S. Dietmann,et al.  Mitochondrial RNA modifications shape metabolic plasticity in metastasis , 2022, Nature.

[4]  S. Ran,et al.  Inhibiting NADPH Oxidases to Target Vascular and Other Pathologies: An Update on Recent Experimental and Clinical Studies , 2022, Biomolecules.

[5]  Zuojia Liu,et al.  Combined Levo-tetrahydropalmatine and diphenyleneiodonium chloride enhances antitumor activity in hepatocellular carcinoma. , 2022, Pharmacological research.

[6]  H. Hua,et al.  Targeting extracellular matrix stiffness and mechanotransducers to improve cancer therapy , 2022, Journal of Hematology & Oncology.

[7]  Mengsu Yang,et al.  Single cell analysis of mechanical properties and EMT-related gene expression profiles in cancer fingers , 2022, iScience.

[8]  Yolima P. Torres,et al.  TRP Channels as Molecular Targets to Relieve Cancer Pain , 2021, Biomolecules.

[9]  H. Hua,et al.  Targeting Akt in cancer for precision therapy , 2021, Journal of Hematology & Oncology.

[10]  J. Onuchic,et al.  Decoding leader cells in collective cancer invasion , 2021, Nature Reviews Cancer.

[11]  F. Fieschi,et al.  NADPH Oxidases (NOX): An Overview from Discovery, Molecular Mechanisms to Physiology and Pathology , 2021, Antioxidants.

[12]  Shuangxi Chen,et al.  Mitochonic acid 5 regulates mitofusin 2 to protect microglia , 2021, Neural regeneration research.

[13]  T. Velten,et al.  Microfluidic In Vitro Platform for (Nano)Safety and (Nano)Drug Efficiency Screening. , 2021, Small.

[14]  J. Sage,et al.  Mechanisms of small cell lung cancer metastasis , 2020, EMBO molecular medicine.

[15]  J. Choi,et al.  Matrix stiffness epigenetically regulates the oncogenic activation of the Yes-associated protein in gastric cancer , 2020, Nature Biomedical Engineering.

[16]  E. Sikora,et al.  Inhibition of NADPH Oxidases Activity by Diphenyleneiodonium Chloride as a Mechanism of Senescence Induction in Human Cancer Cells , 2020, Antioxidants.

[17]  Andrey Rzhetsky,et al.  Automated microfluidic platform for dynamic and combinatorial drug screening of tumor organoids , 2020, Nature Communications.

[18]  T. Minamoto,et al.  Glycogen Synthase Kinase 3β in Cancer Biology and Treatment , 2020, Cells.

[19]  E. Mishima,et al.  Mitochondrial dysfunction underlying sporadic inclusion body myositis is ameliorated by the mitochondrial homing drug MA-5 , 2020, bioRxiv.

[20]  L. Scorrano,et al.  The cell biology of mitochondrial membrane dynamics , 2020, Nature Reviews Molecular Cell Biology.

[21]  F. Che,et al.  Diphenyleneiodonium chloride synergizes with diazoxide to enhance protection against amyloid β induced neurotoxicity. , 2019, Journal of integrative neuroscience.

[22]  Yugang Jiang,et al.  Mitochonic acid‐5 attenuates TNF‐α‐mediated neuronal inflammation via activating Parkin‐related mitophagy and augmenting the AMPK–Sirt3 pathways , 2019, Journal of cellular physiology.

[23]  Yan Zhao,et al.  Higher matrix stiffness as an independent initiator triggers epithelial-mesenchymal transition and facilitates HCC metastasis , 2019, Journal of Hematology & Oncology.

[24]  H. Hua,et al.  Targeting mTOR for cancer therapy , 2019, Journal of Hematology & Oncology.

[25]  Daniela Pankova,et al.  RASSF1A controls tissue stiffness and cancer stem‐like cells in lung adenocarcinoma , 2019, The EMBO journal.

[26]  G. Casazza,et al.  Role of liver and spleen stiffness in predicting the recurrence of hepatocellular carcinoma after resection. , 2019, Journal of hepatology.

[27]  L. Galluzzi,et al.  Mitochondrial metabolism and cancer , 2017, Cell Research.

[28]  O. Ohara,et al.  Mitochonic Acid 5 (MA-5) Facilitates ATP Synthase Oligomerization and Cell Survival in Various Mitochondrial Diseases , 2017, EBioMedicine.

[29]  Konstantinos Konstantopoulos,et al.  Cancer cell motility: lessons from migration in confined spaces , 2016, Nature Reviews Cancer.

[30]  Denis Wirtz,et al.  Engineered Models of Confined Cell Migration. , 2016, Annual review of biomedical engineering.

[31]  Pei-Hsun Wu,et al.  Confinement Sensing and Signal Optimization via Piezo1/PKA and Myosin II Pathways , 2016, Cell reports.

[32]  T. Abe,et al.  Mitochonic Acid 5 (MA-5), a Derivative of the Plant Hormone Indole-3-Acetic Acid, Improves Survival of Fibroblasts from Patients with Mitochondrial Diseases. , 2015, The Tohoku journal of experimental medicine.

[33]  S. Merajver,et al.  Single-cell Migration Chip for Chemotaxis-based Microfluidic Selection of Heterogeneous Cell Populations , 2015, Scientific Reports.

[34]  Andrew Callan-Jones,et al.  Confinement and Low Adhesion Induce Fast Amoeboid Migration of Slow Mesenchymal Cells , 2015, Cell.

[35]  Mehmet Toner,et al.  Collective and Individual Migration following the Epithelial-Mesenchymal Transition , 2014, Nature materials.

[36]  J. Smith,et al.  Transient receptor potential vanilloid 1 (TRPV1) antagonism in patients with refractory chronic cough: a double-blind randomized controlled trial. , 2014, The Journal of allergy and clinical immunology.

[37]  Yi Luan,et al.  Transient receptor potential (TRP) channels, promising potential diagnostic and therapeutic tools for cancer. , 2014, Bioscience trends.

[38]  Lidong Qin,et al.  Mesenchymal-mode migration assay and antimetastatic drug screening with high-throughput microfluidic channel networks. , 2014, Angewandte Chemie.

[39]  P. Friedl,et al.  Classifying collective cancer cell invasion , 2012, Nature Cell Biology.

[40]  K. Stroka,et al.  Physical confinement alters tumor cell adhesion and migration phenotypes , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[41]  Matthew R. Dallas,et al.  Chemotaxis of Cell Populations through Confined Spaces at Single-Cell Resolution , 2012, PloS one.

[42]  Georg Krupitza,et al.  Initial steps of metastasis: Cell invasion and endothelial transmigration , 2011, Mutation research.

[43]  R. Weinberg,et al.  A Perspective on Cancer Cell Metastasis , 2011, Science.

[44]  Petra S Dittrich,et al.  Advances in microfluidics for drug discovery , 2010, Expert opinion on drug discovery.

[45]  Gwo-Bin Lee,et al.  Microfluidic cell culture systems for drug research. , 2010, Lab on a chip.

[46]  Claudio G. Rolli,et al.  Impact of Tumor Cell Cytoskeleton Organization on Invasiveness and Migration: A Microchannel-Based Approach , 2010, PloS one.

[47]  B. Chizh,et al.  The effects of the TRPV1 antagonist SB-705498 on TRPV1 receptor-mediated activity and inflammatory hyperalgesia in humans , 2007, Pain.

[48]  A. Manz,et al.  Lab-on-a-chip: microfluidics in drug discovery , 2006, Nature Reviews Drug Discovery.